Introduction
Left ventricular assist devices (LVADs) have emerged as a mainstay of therapy for patients with advanced refractory left ventricular heart failure (HF). 1, 2 In recent years we have seen a shift from large, space occupying pulsatile systems to small, rotary continuous-flow pumps (cf-LVADs). 3 With this shift in design, a progressive increase in survival has been observed. 4 However, despite this overall outcome improvement, an accompanying rise in adverse events-notably device-related thrombosis, thromboembolic events and adverse neurologic sequelae-has been detected. 5 -8 LVAD-related thrombosis, in contrast to conventional vascular damage or inflammation-mediated thrombosis, is largely driven by supraphysiologic levels of shear stress imparted to blood elements, notably platelets, upon passage through the pump. 9, 10 To provide perspective, shear stress in normal blood flow is typically below 60 dyne/cm 2 , 11 whereas in the case of cf-LVADs it may range to 500-1000 dyne/cm 2 or beyond. 12, 13 The trigger of these complications is multi-factorial: they can be driven by intra-or extra-device issues, e.g. gap clearance changes over time with protein deposition, or disturbed flow conditions associated with angulation of inflow/outflow cannula, 7, 14, 15 all of which alter the total shear stress exerted on circulating platelets. Further, with recirculation, accumulation of cyclic exposure to 'hypershear' may impart significant platelet damage leading to progressively enhanced shear stress-mediated platelet activation (SMPA) that ultimately leads to thrombotic events. 16 To date, the ability to clinically assess the platelet response to shear stress and the platelet pro-thrombotic profile have been lacking. At present, the evaluation of the efficacy of antithrombotic therapy in LVAD patients largely consists in measuring the effect of anticoagulants on the coagulation cascade. In the setting of LVAD therapy, the international normalized ratio/activated partial thromboplastin time (INR/aPTT) are routinely monitored according to the international guidelines on anticoagulation management of patients implanted with mechanical circulatory support devices. 17 However, these coagulation parameters have proven inadequate as predictors of, or to correlate with altered platelet function and thrombotic episodes. Moreover, although thromboelastography is a recognized valuable method for monitoring platelet activation and blood pro-coagulant activity, it remains far from effective clinical translation and scarcely used in routine clinical practice.
The platelet activity state (PAS) assay is a unique assay that has been developed specifically to assess SMPA. In previous pre-clinical studies, we reported that PAS assay is a sensitive tool to monitor in vitro the progression of SMPA over consecutive/cyclic exposure of platelets to haemodynamic hypershear stress patterns pertinent to mechanical blood therapeutic recirculating devices, such as prosthetic heart valves, 18, 19 blood oxygenators, 20 LVADs, 21, 22 and the total artificial heart. 23, 24 The PAS assay is performed on gel-filtered platelets and plasma coagulation factors are eliminated during the platelet isolation procedure. As such, the PAS assay does not account for the effect of oral anticoagulants on plasma coagulation, allowing to selectively and specifically focus the analysis on platelet function.
. The PAS assay utilizes as substrate acetylated prothrombin, which upon exposure to damaged, activated platelet membranes resulting from elevated shear stress exposure, is converted to thrombin, which is measured as a surrogate marker of activation. 25 Thrombin generated by conversion of acetylated prothrombin does not feedback to further activate platelets nor convert fibrinogen to fibrin. This represents the distinctive and more innovative feature of PAS assay, allowing assay of thrombin generation to serve as a clear indicator of the SMPA level. 25 Previous studies have shown that PAS assay correlates well with platelet P-selectin 26, 27 and annexin V 27, 28 expression, as quantified with flow cytometry. Moreover, previous studies have shown that the PAS assay is sensitive to the effect of platelet-metabolized antiplatelet drugs. 22, 29 In the present study we hypothesized that the PAS assay would serve as a sensitive tool for monitoring the natural history of SMPA clinically in vivo in LVAD implanted patients.
Methods

Study population and data analysis
This study is a cross-sectional observational study performed at San Raffaele Scientific Institute in Milan, Italy. The study complies with the Declaration of Helsinki. Institutional review board approval was obtained before patient enrolment and all patients provided informed consent before participation in the study.
Between March 2015 and June 2017, 68 cf-LVAD patients entered the study. In detail, all consenting patients who received a durable LVAD between January 2011 and June 2017 were enrolled.
Study endpoints included serial measurement of PAS values as well as assessment of the correlation between the occurrences of LVAD-related thromboembolic complications with PAS values.
PAS values were measured at multiple time points: (i) 48 h before LVAD implantation (pre-implant), to define patient-specific baseline values; (ii) in the early post-implant and during long-term follow-up (i.e. at 1, 3, 6, 12, 18, and 24 months post-implant). Early-post implant PAS values were measured following 1 month from the LVAD procedure. This was dictated by the need to get patients' postoperative stable clinical conditions, which is typically recovered following the first-month post-implant rehabilitation programme. Follow-up visits were performed at the LVAD outpatient clinic of our Institute according to the clinical plan of patients' follow-up.
For patients who developed an event, PAS was measured during the hospital stay within the 24 h that followed event occurrence.
To define laboratory specific ranges for normal PAS values, we analysed PAS in healthy volunteers (n = 25) without a history of prior bleeding or thrombosis, recruited from hospital staff, matched for age and sex.
Data on patient demographics, medical history, INTERMACS class, pre-implant short-term mechanical circulatory support (i.e. intra-aortic balloon pump, Impella, extracorporeal membrane oxygenation), laboratory and diagnostic analyses, anticoagulation and antiplatelet therapy, and coagulation parameters (platelet count, aPTT, INR) were also recorded and considered in our analysis.
Definition of thrombotic events
Pump thrombosis was defined as an obstructive thrombus within the blood contacting surfaces of device inflow cannula, outflow conduit or grafts, associated with clinical signs of major impaired pump performance or pump malfunction (e.g. decreased pump flow, need to increase pump speed/power, or haemolysis), or the need for thrombolytic or surgical intervention. 30 A stroke event was defined as a neurological deficit lasting more than 24 h or less than 24 h with a brain imaging study showing new infarction. 30 In particular, ischaemic stroke was defined as the new appearance of a hypodense image on non-contrast cerebral computed tomography whose location is compatible with clinical signs and symptoms. 30 The platelet activity state assay
The PAS assay was originally described by Jesty and Bluestein. 25 The experimental protocol of PAS assay used in this study has been fully described in Valerio et al. 31 Briefly, 20 mL of whole blood was drawn via venipuncture from consenting LVAD candidates/recipients and collected into 2 mL acid-citrate dextrose. PAS measurements were performed within 2 h of blood sampling. Platelets were isolated from blood via gentle centrifugation (170 g, 10 min) and column-gel filtration of platelet-rich plasma. 31 Purified platelets were exposed to a modified prothrombin precursor reagent, i.e. acetylated prothrombin (Ac-FII), to quantify the thrombin production rate of platelets, as the marker of SMPA. 25, 31 Platelets were incubated with Ac-FII for 10 min at 37 ∘ C, in the presence of activated Factor X (FXa) and Ca 2+ (final concentrations: 5000 platelets/ L, 200 nM Ac-FII, 100 pM FXa, and 5 mM Ca 2+ ). 31 The thrombin generation rate was quantified through spectrophotometric analysis (Multiskan FC Microplate, ThermoFisher Scientific, Waltham, MA, USA) using Chromozym-TH (Roche Diagnostics, Indianapolis, IN, USA) as the thrombin-specific chromogenic peptide substrate. 31 Kinetic absorbance readings were performed at room temperature at 405 nm wavelength for 8 min. PAS values were calculated as the slope of the linear fitting of the absorbance-time data points, over the 8 min kinetic reading.
PAS values were obtained for isolated platelets and normalized against those obtained by sonicating platelets from the same donor (Misonix Microson microprobe sonicator, Qsonica Llc, Newtown, CT, USA; sonication conditions: 10 W, 10 s). The sonication step yields platelets with maximal prothrombinase activity 31 ; thus, normalized PAS values [expressed as percentage, PAS (%)] represent the bulk activity as a fraction of the thrombin generation rate of sonicated platelets (100%). For each PAS measurement, multiple (n = 8) readings were performed to evaluate data reproducibility.
The PAS experimental protocol was designed to guarantee test-retest reliability and validity, and to evaluate inter-operator and intra-operator variability. For each experiment, two different operators performed the test on two independent platelet samples obtained from the same patient. Each test was performed in duplicate: specifically, each operator repeated the test twice over a short period of time. The same experimental tools and instruments were utilized under analogous experimental conditions. To maintain objectivity and avoid bias, blood samples were obtained and processed by individuals blinded as to the occurrence of adverse events.
Statistical analysis
Categorical data are presented as absolute numbers and percentages and were compared by two-tailed 2 (25th and 75th percentiles) for non-normally distributed variables. Continuous measurements were compared using Student's t-test or Mann-Whitney U test for normally and non-normally distributed values, respectively. Two-sided significance test was used throughout. Non-parametric ANOVA on ranks was calculated for the repeated PAS values over time and to compare PAS values associated with different pumps. Receiver-operating characteristic (ROC) curves were performed to identify the cut-off value of PAS. A P-value of <0.05 was considered statistically significant. Statistical analysis was performed with the STATA software (version 13; Stata Corp., College Station, TX, USA).
Results
Overall, 68 patients were evaluated over a median follow-up of 602 (234-942) days. Baseline demographic and clinical characteristics of the patients are reported in Table 1 .
LVADs were implanted as follows: HeartMate II (HM2; Thoratec Corp., Pleasanton, CA, USA) in 15 patients (22%); HVAD (HeartWare Corp., Miami, FL, USA) in 38 patients (56%); HeartMate 3 (HM3; Abbott Laboratories, Chicago, IL, USA) in 15 patients (22%). The intention to treat was destination therapy for all the patients. Anticoagulation was managed with warfarin [oral anticoagulation (OAC)] targeted to INR 2-2.5 and acetylsalicylic acid (ASA). All patients were bridged with intravenous anticoagulation in the early post-implant phase. ASA dose varied with the pump type according to LVAD management guidelines of our Institute: specifically, HM2 and HM3 patients were prescribed ASA 100 mg/day; HVAD patients were prescribed ASA 300 mg/day. Eleven (16%) patients were withheld from ASA over the course of support because of bleeding complications and were managed with warfarin alone. Table 2 shows the incidence of thromboembolic complications. Six patients (9%) suffered a thrombotic adverse event, namely two (3%) patients suffered pump thrombosis requiring pump exchange, and four (6%) patients developed an ischaemic stroke. Median time between LVAD implantation and development of a thrombotic event was 232 (143-831) days.
Incidence of left ventricular assist device post-implant complications
All patients who experienced an adverse event were on combined antithrombotic therapy (OAC + ASA). No interruptions of anticoagulation, alterations of the antiplatelet regimen, or arrhythmias (atrial fibrillation/ventricular tachycardia) were recorded for these patients. Figure 1 shows the dynamics of SMPA as measured via the PAS assay: according to our analysis, PAS values did not change significantly over the time of LVAD support (P = 0.15). An overall median PAS value of 0.45% (0.33%-0.75%) was recorded, which was not statistically different with respect to PAS measured in healthy volunteers [0.48% (0.42%-1.01%, P = 0.10]. The HM2 axial pump was associated with a distinct footprint in terms of PAS as compared with the HVAD and HM3 centrifugal pumps (P = 0.020 and P = 0.016, respectively) ( Figure 2) . Conversely, no significant differences were observed between HVAD and HM3 (P = 0.47). This result indicates that the test effectively discriminates different activation dynamics mediated by platelet recirculation through the different LVAD models (axial vs. centrifugal pumps).
Dynamics of platelet activation
No differences in PAS values were observed by comparing patients treated with combined antithrombotic therapy [OAC + ASA, PAS 0.44% (0.30%-0.72%)] vs. those with OAC alone [PAS 0.45% (0.37%-0.62%); P = 0.71].
A the time of any thromboembolic complications, PAS was 15-fold higher than in the rest of the population [6.67% (5.59%-11.98%) vs. 0.45% (0.33%-0.75%); P = 0.012] (Figure 3A) , despite comparable coagulation profile (Table 3) . Moreover, PAS at event was significantly different (14-fold higher) than PAS in healthy volunteers ( Figure 3A ; P = 0.033).
At univariate analysis, neither patient demographics nor clinical variables were predictive of the occurrence of post-implant thrombotic events (Table 3) With regard to antithrombotic therapy, univariate analysis did not identify a role for combined (OAC + ASA) or single (OAC alone) therapy in the development of events (P = 0.58).
Lactate dehydrogenase (LDH) was only partially able to predict thrombotic complications. Indeed, retrospective analysis of LDH values measured before the event occurrence (supplementary material online, Table S1) revealed that only one patient implanted with the HM2 who suffered pump thrombosis presented an LDH value of 738 IU/L, i.e. higher than the 600 IU/L LDH threshold of haemolysis. 32 At univariate analysis, only PAS values were associated with adverse events. Indeed, a statistically significant difference was recorded for PAS at event vs. the control population (P = 0.012), highlighting specificity for PAS in detecting elevated values of SMPA associated with clinically diagnosed thrombotic complications.
Notably, baseline PAS values (i.e. pre-implant; Figure 3B ) were also associated with the development of thrombotic events during the course of LVAD support: pre-implant PAS values measured in patients who suffered a thrombotic complication [1.90% (1.24%-3.17%)] were significantly higher than in the rest of the population [0.42% (0.32%-0.72%); P = 0.006], suggesting a potential pro-thrombotic profile of these patients.
ROC curves identified a pre-implant PAS cut-off value of 1.05% (sensitivity and specificity of 100% and 84%, respectively). As for post-implant PAS associated with thromboembolic complications, a cut-off value of 3.26% was identified (sensitivity 100%, specificity 97%) (supplementary material online, Figure S1 ).
Discussion
In this study we examined the utility of the prothrombinase PAS assay to evaluate SMPA in cf-LVAD patients during the preoperative, early post-implant, and long-term follow-up stages. The present study is the first report of the use of the PAS assay clinically to evaluate the effect and extent of platelet exposure to shear in . We show that SMPA as measured via the PAS assay did not increase significantly in the overall population over time, indicating that modern cf-LVADs do not enhance significant platelet activation during normal pump operation. Conversely, in the presence of any triggering mechanism driving thrombosis, evident elevations of SMPA and altered PAS values were observed (P = 0.012).
Aberrant shear stress conditions lead to the development of thrombotic adverse events in only few patients (9%): whether this is the result of patient-specific pump-related issues-e.g. within the LVAD vs. particular LVAD inflow cannula placement or outflow graft angulation, 33 ventricular-LVAD tissue ingrowth, or triggered by patient-specific genetic susceptibilities-remains unknown and is a subject to future investigation. On the other hand, regardless of the trigger mechanism, the PAS assay demonstrated the clinical competence to correlate with those phenomena on a patient-specific basis. Indeed, univariate analysis identified PAS measured preoperatively as a discriminator between the sub-group of patients who did vs. who did not develop a thrombotic event (P = 0.006). This suggests that patient-specific platelet susceptibility to activation might constitute a clinical predisposing factor, which becomes overt when the contribution of LVAD-induced shear stress is added. These data highlight a potential thrombotic risk prediction capability for PAS associated with pre-existing platelet damage. Conversely, none of the other preoperative parameters ( Table 3 ) demonstrated such a predictive power, consistent with previous studies.
8,34 -38 Over the last few years, the PAS assay has been utilized extensively for in vitro pre-clinical studies of device-associated SMPA.
16,18 -29 However, no studies have utilized the PAS assay for monitoring SMPA in the clinical setting. Steinlechner and colleagues simultaneously utilized thrombelastography, rotation thromboelastometry, and the multiplate analyser, to monitor platelet activation in 12 patients supported with cf-LVADs. 39 Despite demonstrating markedly impaired platelet function in LVAD recipients, data on the correlation with adverse events were not provided. 39 In a small pilot study, our group recently reported an initial attempt to assess SMPA via the PAS assay, as a clinically relevant diagnostic tool. 31 Herein we have applied and extended this methodology to a larger population, also examining the predictive characteristics of the PAS assay. We exclude that the PAS assay experimental protocol for platelet isolation might induce platelet activation enhancing thrombin generation. Indeed, the experimental campaign performed on healthy volunteers showed that none of the platelet sample in this control population presented an activated prothrombotic profile [median PAS value of 0.43% (0.39%-0.47%)].
In this study, we observed an overall incidence of thrombotic events in 9% of our cohort, without evidence of a direct influence of either type of LVAD (axial or centrifugal, P = 0.39) or antiplatelet regimen (P = 0.58). Accordingly, two relevant observations may be drawn. The first one is that, although axial and centrifugal pumps differ significantly regarding geometric and functional properties, and are characterized by significantly different impeller rotational velocities and distribution of shear stress in the flow field, the pump specifically is not the sole determinant of event triggering. This was clinically demonstrated in this study, suggesting a concurrent patient-specific tendency to develop post-implant complications. On the other hand, despite the fact that all patients implanted with the same device are exposed to analogous extents of shear stress injury, we acknowledge that specific LVAD surgery-related factors (i.e. inflow/outflow cannula angulation) might have contributed in sustaining elevations of SMPA over time enhancing the development of thromboembolic complications. We also exclude that different pump working conditions (i.e. rotational speed in the event vs. free-of-event population) may have a direct effect on triggering thromboembolic complications (HM2: P = 0.70; HVAD: P = 0.97), also confirming previous findings. exhibited comparable tendency to develop adverse events as compared to the HVAD population ( Table 2) . Results obtained in the HM3 group are consistent with lower PAS values characterizing this pump (Figure 2 ). However, due to limited number of recorded adverse events, data related to inter-device differences should be treated with caution. Moreover, we acknowledge that only thrombotic events were analysed in this study while the analysis of LVAD haemocompatibility would refer to the evaluation of both bleeding and thrombosis events, which often aggregate together in the same individual. 40 As far as the second observation is concerned, the detrimental effect of shear stress does not seem to be predictably mitigated by antiplatelet therapy. In fact, we did not observe a role for combined (OAC + ASA) or single (OAC alone) therapy in modulating the incidence of thromboembolic complications. Furthermore, our study indicates that different ASA dose (HM2 and HM3: 100 mg/day vs. HVAD: 300 mg/day) was not a major determinant for the occurrence of thromboembolic complications. Our findings are consistent with previous reports and recent mechanistic studies that questioned the role of ASA in modulating platelet response in the setting of cf-LVAD therapy. 41 -43 Moreover, our results further extend the 2-year endpoint of the EU TRACE study 44 providing clinical evidences that the biochemical pathway of SMPA and the associated platelet prothrombotic profile are at least minimally modulated by ASA therapy in LVAD patients.
Notably, the coagulation profile (platelet count, aPTT and INR values) did not differ between the two populations (event vs. no event, Table 3 ), consistent with previously reported clinical trials. 6 We also report that LDH was not predictive of thrombotic complications in HVAD patients. The discrepancy between elevated SMPA vs. low LDH levels may be explained by the fact that red blood cells are much more resistant to shear-mediated damage than platelets. 45 From this perspective, assessment of SMPA via PAS assay offers the potential to serve as a more sensitive marker of LVAD-related thrombotic complications.
Study limitations
In patients with thromboembolic complications, the test was performed when the adverse event was clinically overt: as such, the earlier phases of this phenomenon are still a blind spot. Indeed, while the time points for follow-up visits were chosen utilizing real-life clinical flow of patients undergoing LVAD implantation, time points related to a clinical event were unpredictable, preventing the possibility of monitoring PAS values early before the event occurrence. Accordingly, while we show higher pre-implant PAS values in patients who experienced a thrombotic complication, following LVAD implantation we were not able to observe elevation of PAS early before the event occurrence. In addition, although our results obtained with the PAS assay are promising, our data are to be considered a first step in exploring . the role of strategies addressing the issue of SMPA as a relevant key factor driving adverse events in LVAD patients. To establish the PAS assay as a clinically relevant diagnostic tool, additional studies with a larger cohort of patients, longer-term analyses, and further multicentre trials are warranted. Increasing the number of patients will also allow evaluation of the correlation between SMPA and thromboembolic events on the basis of the LVAD intention to treat (destination therapy vs. bridge to transplantation).
Future perspective
While SMPA largely underlies cf-LVAD thrombotic adverse events, 16 to date its clinical assessment has been elusive. Understanding the predisposing risk factors of thrombotic complications is critical to devising effective preventive strategies. The possibility of identifying pre-existing-and often persisting-abnormalities in platelet function in patients even before a device is implanted may have important implications in the context of LVAD support and may limit progression of potentially life-threatening outcomes. However, at present, a paucity of effective prognostic biomarkers allowing for rapid and reliable prediction of the risk of thrombotic complications exists. Monitoring of patients' coagulation status through INR alone has been shown to be ineffective in preventing adverse events. As INR is measured in platelet-poor plasma, it is inherently unable to monitor platelet function. As a result, other clinical predictors are critical to stratify the likelihood of occurrence of thrombotic events on an individual patient basis. Integrating PAS with standard INR analysis of coagulation would afford more comprehensive evaluation of a given patient's haemostatic system and associated patient-specific thrombotic risk.
Prospectively, the PAS assay might also be applied for spotting patient-specific platelet response to antiplatelet medications: it may allow identifying individual poor responsiveness to drugs and facilitate the tailoring of individualized antiplatelet strategies (i.e. advanced/reduced antiplatelet dose and/or administration of different molecules, i.e. P2Y 12 inhibitors).
With this study we also set the basis for the future development of a next-generation point-of-care diagnostic device for bedside and/or home-based antithrombotic therapy monitoring. Our group has recently reported on the development and use of microfluidic technology to address this aim. 29, 46, 47 Such a system will enhance standardization of the method via automating procedural steps, thus reducing the risk of random/systematic users' errors to affect the results. Moreover, it will further enhance the assay scale-ability and reproducibility as well as shortening assay time. Such development and validation of PAS may aid overcoming limitations of this study. Indeed, it may allow systematic (i.e. routine) monitoring of PAS values enhancing the identification of an increasing trend early before the event occurrence that would advise of an increased thrombotic risk. In this context, such a system may have significant impact on limiting the likelihood of adverse events, improving the quality of life of patients and reducing overall healthcare burden.
Conclusions
The PAS assay is a sensitive means of assaying platelet activation and can be readily measured in LVAD patients. Here we show that PAS correlates with altered levels of platelet activation associated with thromboembolic complications. Our study also reveals that a pre-implant background difference in platelet activation might characterize patients who sustained thromboembolic complications. Post-implantation, a concurrent role of patient susceptibility, pump haemodynamics-related issues and accumulation of platelet damage due to repeated exposure to hypershear is suggested as the ultimate trigger of thrombosis. The identification of patients with a specific activated prothrombotic profile might guide the development of refined patient-tailored pharmacological strategies. Our results also encourage and support further studies examining platelet activation as measured via the PAS assay as a target for new antithrombotic agents and for technological improvements of LVAD design.
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